| Identification | Back Directory | [Name]
4-(3,4-Dihydro-6,7-diMethoxy-2(1H)-isoquinolinyl)-N-[2-(3,4-diMethoxyphenyl)ethyl]-6,7-diMethoxy-2-quinazolinaMine Monohydrochloride | [CAS]
142715-48-8 | [Synonyms]
CP-100356 Monohydrochloride
4-(3,4-Dihydro-6,7-diMethoxy-2(1H)-isoquinolinyl)-N-[2-(3,4-diMethoxyphenyl)ethyl]-6,7-diMethoxy-2-quinazolinaMine Monohydrochloride | [Molecular Formula]
C31H37ClN4O6 | [MDL Number]
MFCD00911858 | [MOL File]
142715-48-8.mol | [Molecular Weight]
597.102 |
| Chemical Properties | Back Directory | [storage temp. ]
2-8°C | [solubility ]
DMSO: >5mg/mL | [form ]
powder | [color ]
white to off-white | [InChIKey]
WWCHXVYTCMPAMV-UHFFFAOYSA-N | [SMILES]
Cl.COc1ccc(CCNc2nc(N3CCc4cc(OC)c(OC)cc4C3)c5cc(OC)c(OC)cc5n2)cc1OC |
| Hazard Information | Back Directory | [Chemical Properties]
Off-White to Light Tan Solid | [Uses]
CP-100356 is a specific inhibitor of MDR1 (P-Gp), the protypical ABC transporter. CP-100356 also inhibits prazosin transport in human breast cancer resistance protein (BCRP)-transfected MDCKII cells, suggesting that it acts as a dual inhibitor. CP-100356 does not inhibit multidrug resistance-associated protein 2 (MPR2 IC50 >15 mM). | [in vivo]
CP-100356 (6-24 mg/kg; p.o.) increases the systemic exposure of Fexofenadine (36- and 80-fold increase in Cmax and AUC at the dose of 24 mg/kg) in rats[1]. | [storage]
Desiccate at RT |
|
| Company Name: |
BOC Sciences
|
| Tel: |
|
| Website: |
https://www.bocsci.com |
| Company Name: |
Energy Chemical
|
| Tel: |
021-58432009 400-005-6266 |
| Website: |
http://www.energy-chemical.com |
|